Panel · Use case · Quality
Site Transfer Round Table.
LiveRound TableConvene quality, regulatory, clinical operations and business development on moving manufacturing of a product to a new site.
Site Transfer Round Table is a ready-made use case for Quality. It ships under the Round Table template.
For quality and supply leads. You get each discipline's view in its own terms, where they connect and disagree, what none covered and what the deliberation does not settle. Claims are cited or marked as gaps.
Add it to your library to reuse from New → From template. Edit the saved copy in your library on the service form.
The decision
Should manufacturing of a late-stage product be transferred to a new contract site?
Who is at the table
A site change for a late-stage product touches the quality system, the regulatory file and the clinical supply. ICH Q12 and Q10 give the frame for managing a change across the product’s life.
| Seat | What it is asked | What it works from |
|---|---|---|
| Director Quality Assurance | What comparability and process validation would be needed and how the transfer is controlled.1 | ICH Q10 (pharmaceutical quality system) and ICH Q12 (lifecycle management). |
| Regulatory Strategist | Which regulatory filings the change triggers and the effect on timelines.1 | ICH Q12 and regional change rules. |
| Clinical Operations Director | Whether trial supply continues and whether the new site’s material can be used in ongoing studies. | Supply plans and study timelines. |
| Ecosystem Intelligence Orchestrator | What the contract terms, capacity and counterparty risk look like. | Company disclosures and contract practice. |
What the round table does
A transfer is a change to manage. The panel treats it as a change under the quality system and says what documentation each step needs. It marks every requirement that depends on the product type.1
Comparability is the crux for biologics. For a biological product, a change in manufacturing site may require a comparability exercise. The panel names the quality seat’s view on what is needed and marks it as depending on the product.1
Supply risk is a trade-off. The panel sets the risk of staying (capacity, single-site dependence) against the risk of moving (delay, comparability, inspection), without ranking them.
Recommended length
Standard
Four disciplines bear on this question. Standard depth gives each a seat, with the table of connections and the dissent, in about four pages.
You can pick another length on the form. The other two stay available.
Assumptions the round table checks
The round table states the assumptions each seat relies on, and says what each gap limits. Examples for this question:
- The product is eligible for a lifecycle-managed change.
- The new site has a satisfactory inspection history.
- The process can be reproduced at the new scale and equipment.
Standards, guidance and sources
Frame
The decision practice behind the memo itself is on the template page.
What gets flagged
Any requirement that depends on product type and has not been confirmed, any timeline not supplied by the sponsor, and any claim about the new site that rests on its own marketing.
What arrives
- The question, and who was asked
- Where the panel lands
- What each discipline says
- Where the disciplines connect
- Where they disagree, and why it matters
- What none of them covered
- What changes, and what this does not cover
What it will not do
It is a deliberation of AI specialists and not a vote of human experts. It reports where they land and where they split, and the decision stays with you.
It is not a quality audit or a regulatory filing strategy.
It is not a vote of human experts. Every seat is an AI specialist, and the report says so.
It does not add a seat that did not speak or invent a quote or a number.
It does not decide. It sets out the views, the dissent and the gaps for you to decide.
References
- [1] International Council for Harmonisation. Quality guidelines, including Q10 (Pharmaceutical Quality System) and Q12 (Technical and regulatory considerations for pharmaceutical product lifecycle management). Known from the ICH guidelines listing; the guidelines were not read.
Links checked 9 October 2026
These are the sources the template drew on. None of their authors or issuers has reviewed it.
About the Panel service
Each panelist answers in their own voice, then the discussion is drawn together. You get the question and who was in the room, every position in full, what they agreed on, where they split, and what follows. Disagreements are written down rather than smoothed into a consensus nobody actually holds, because the split is usually the part you needed.
To edit a saved template, open New → Panel → From template, or the library rail on the service form.